Iridex Says Local Coverage Determination L39620 Micro-Invasive Glaucoma Surgery Will Likely Materially Limit The Patient Types For Which WPS Government Health Administrator Will Reimburse Cyclophotocoagulation Procedures After December 24, 2023 - 8K
Portfolio Pulse from Benzinga Newsdesk
Iridex has announced that the Local Coverage Determination L39620 Micro-Invasive Glaucoma Surgery will likely limit the patient types for which WPS Government Health Administrator will reimburse Cyclophotocoagulation procedures after December 24, 2023. This decision by WPS, a Medicare Administrative Contractor, could impact the use of Iridex's Cyclo G6 Laser System and Probe Delivery Devices in ophthalmology.
November 01, 2023 | 10:49 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The decision by WPS could limit the use of Iridex's Cyclo G6 Laser System and Probe Delivery Devices, potentially impacting the company's revenues.
The decision by WPS to limit the patient types for which it will reimburse Cyclophotocoagulation procedures could lead to a decrease in the use of Iridex's Cyclo G6 Laser System and Probe Delivery Devices. This could result in a decrease in the company's revenues, negatively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100